Affordable two-chip Beacon Select system to
broaden customer access to innovative high throughput,
function-first antibody discovery capabilities
EMERYVILLE, Calif., May 15, 2023
/PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell
biology company, today announced the launch of Beacon
Select™ optofluidic system with Opto® B
Discovery workflows for antibody discovery.
The Opto B Discovery workflows, with their cutting-edge
technologies and features, enable scientists to find lead candidate
antibodies tailored to their specific challenges and changing
needs. Combined with the value-matched Beacon Select system, more
customers may access these propriety antibody discovery
applications, but with the optimum level of features that meet
their research and budgetary needs. PhenomeX's optofluidic platform
is now a standard to deliver optimal antibodies with speed, as
highlighted recently in the high-impact journal Cell, where
antibodies against COVID-19 variants were discovered on the Beacon
system six months before Omicron emergence.
Beacon Select for Antibody Discovery Workflow Feature
Opto B Discovery workflows on the Beacon Select system enable
scientists to accelerate antibody screening and hit generation to
find lead candidate antibodies and are ideally suited for small- to
mid-sized biopharma and CDMOs/CROs. This contrasts with the
flagship four-chip Beacon system enabled for antibody discovery,
optimized for the highest screening throughputs demanded by large
biopharma and established CDMOs/CROs.
The Beacon Select system enables rapid function-first selection
of single B cells with the best characteristics for any antibody
application, including antibody therapeutics, diagnostics, and
reagents. In addition, the Opto B Discovery workflows offer users
highly customizable assays to assess antigen and epitope
specificity, species or variant cross-reactivity, and functional
properties, all in a single-day workflow. By selecting and
recovering sequences of only the most desirable antibodies with
favorable attributes, users can reduce overall bioprocessing costs,
improve the probability of campaign success, and shorten timelines
to lead candidates. When combined with PhenomeX's catalog of
best-in-class reagents and consumables for mouse, human, and rabbit
B cell repertoires, customers can do all this against even the
hardest antigen targets, including G coupled-protein receptors
(GPCRs) and ion channels, to accelerate antibody discovery beyond
traditional methods available today.
To further increase customer accessibility and affordability,
PhenomeX will offer the Beacon Select system for antibody discovery
with different purchase options including capital placement, lease,
or reagent rental. The two-chip Beacon Select list price will be
approximately half of the current Beacon system, which makes the
technology ideal for new users that do not need the full Beacon
capacity. In addition, this lower price point allows existing
Beacon customers to more readily increase throughput, add
laboratory capacity, and (for existing cell line development
customers) access antibody discovery applications.
PhenomeX participation at 19th Annual PEGS Boston
Conference & Expo
PhenomeX is participating at the 19th annual Protein
Engineering & Cell Therapy Summit (PEGS) conference and expo
being held from May 15-19 at the
Hynes Convention Center in Boston,
Mass. At the conference, the Company will feature its
optofluidic and proteomic platform technologies, including the new
Beacon Select system, in booth #517 and present two posters and
podium presentations. Attendees can explore demonstrations of the
technology and learn more about how PhenomeX's products can advance
and accelerate our understanding of cellular function along the
continuum of scientific discovery, bioprocessing, clinical
research, and immunotherapy development.
Read more about the PhenomeX technology posters and podium
presentations being shared at PEGS at phenomex.com.
About PhenomeX Inc.
PhenomeX is empowering scientists to leverage the full potential
of each cell and drive the next era of functional cell biology that
will advance human health. We enable scientists to reveal the most
complete insights on cell function and obtain a full view of the
behavior of each cell. Our unique suite of proven high-throughput
tools and services offer unparalleled resolution and speed,
accelerating the insights that are key to advancing discoveries
that can profoundly improve the prevention and treatment of
disease. Our award-winning platforms are used by researchers across
the globe, including those at the top 15 global pharmaceutical
companies and approximately 85% of leading U.S. comprehensive
cancer centers.
Forward-Looking Statements
To the extent that statements contained in this press release
are not descriptions of historical facts regarding PhenomeX or its
products, they are forward-looking statements reflecting the
current beliefs and expectations of management. Such
forward-looking statements involve substantial known and unknown
risks and uncertainties that relate to future events, and actual
results and product performance could differ significantly from
those expressed or implied by the forward-looking statements.
PhenomeX undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks
and uncertainties relating to the Company's growth and continual
evolution see the statements in the "Risk Factors" sections, and
elsewhere, in our filings with the U.S. Securities and Exchange
Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phenomex-launches-beacon-select-optofluidic-system-with-opto-b-discovery-workflows-301824598.html
SOURCE PhenomeX